Roferon-A

Roferon-A

a trademark for a parenteral antineoplastic (interferon-alfa-2a).

Roferon-A

A brand name for INTERFERON ALFA-2a.
References in periodicals archive ?
Examples of approved interferon medicines include Betaferon/Betaseron (Bayer), Avonex (Biogen Idec), Rebif (EMD Serono/Pfizer), Laroferon (Roche), Roferon-A (Roche), Canferon (Takeda) and Actimmune (Genentech).
Interferons such as Roferon-A, Intron-A, and Rebetron, used to boost immune response
Roferon-A - licensed only last month - is the first approved treatment for advanced skin cancer.
The market is currently driven by the use of the following immunomodulating agents: Schering-Plough's Intron A (interferon [IFN] alpha-2b), Roche's Roferon-A (IFN alpha-2a) and Novartis' Proleukin (aldesleukin); with new market entrants Bayer/Onyx Pharmaceuticals' Nexavar (sorafenib) and Pfizer's Sutent (sunitinib) making significant inroads into the market in 2006, their first year of sales.
The Roche oncology portfolio also includes NeoRecormon (anaemia in various cancer settings), Bondronat (prevention of skeletal events in breast cancer and bone metastases patients, hypercalcaemia of malignancy), Kytril (chemotherapy and radiotherapy-induced nausea and vomiting) and Roferon-A (hairy cell and chronic myeloid leukaemia, Kaposi's sarcoma, malignant melanoma, renal cell carcinoma).
Other key products include NeoRecormon (anaemia in various cancer settings), Bondronat (prevention of skeletal events in breast cancer and bone metastases patients, hypercalcemia of malignancy), Kytril (chemotherapy and radiotherapy-induced nausea and vomiting) and Roferon-A (leukaemia, Kaposi's sarcoma, malignant melanoma, renal cell carcinoma).
Its franchise includes MabThera (non-Hodgkin's lymphoma), Xeloda (colorectal cancer, breast cancer), Herceptin (breast cancer), NeoRecormon (anemia in various cancer settings), Roferon-A (leukemia, Kaposi's sarcoma, malignant melanoma, renal cell carcinoma), Neupogen (neutropenia) and Kytril (chemotherapy and radiotherapy-induced nausea).
In the Phase III study, Pegasys was administered once weekly at a dose of 180 mcg for 48 weeks, while Roferon-A was administered twice weekly for 12 weeks at a dose of 6 million units followed by 3 million units for 36 weeks (the so-called induction regimen).
Roferon-A is a registered trademark of Hoffmann-La Roche.
Roferon-A is a biological response modifier available in the United States for several types of cancer, including hairy-cell leukemia, AIDS-related Kaposi's sarcoma and Philadelphia Chromosome Positive chronic myelogenous leukemia.
Genentech entered into an agreement with Roche under which Genentech will promote Roche's Roferon-A in the United States for its approved oncology indications.